Bayer reported positive results in a late-stage trial of an experimental stroke prevention medicine, sending its shares up almost 11 per cent on Monday.
The results are a respite for the German conglomerate that has faced declining sales of its blockbuster drugs and ongoing legal challenges in the US.
Patients who took a 50mg daily dose of the inhibitor asundexian alongside a standard anti-platelet therapy were “significantly” at a lower risk of a second stroke compared with those on a placebo, Bayer said. The drug is intended for patients who have already suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, also known as a mini-stroke.
您已閱讀28%（676字），剩余72%（1772字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。